|
01 Oct 2007 |
Preclinical Study Published in Nature Medicine Shows Anti-LINGO-1 AntibodyPromotes Remyelination
|
|
28 Sep 2007 |
Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
|
|
28 Sep 2007 |
Crucell discovers human monoclonal antibodies for the prevention and treatment of the avian flu virus
|
|
27 Sep 2007 |
Herceptin eradicates tumours and may reduce the need for mastectomies in women with inflammatory HER2-positive breast cancer – one of the most aggressive and fastest growing forms of the disease
|
|
27 Sep 2007 |
Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
|
|
26 Sep 2007 |
Biotie has started the first phase I clinical trial with its fully human VAP-1 monoclonal antibody as it has received the final regulatory approval to do so
|
|
26 Sep 2007 |
Abbott and Eisai submit application for adalimumab, the only fully human monoclonal anti-TNFalpha antibody, to treat psoriasis
|
|
26 Sep 2007 |
New Biomarker Data Links KRAS Gene to Vectibix(TM) Clinical Response
|
|
22 Sep 2007 |
Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union
|
|
21 Sep 2007 |
FDA Approves Expanded Labeling for Campath® to Include First-line Treatment for Leading Form of Adult Leukemia
|
|
21 Sep 2007 |
ImClone Systems Expands IMC-A12 Development with Ten New Planned Clinical Trials
|
|
21 Sep 2007 |
Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
|
|
19 Sep 2007 |
LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
|
|
19 Sep 2007 |
Antitope Announces Research Agreement with Fraunhofer Institute for Cell Therapy and Immunology
|
|
14 Sep 2007 |
Genmab Discloses Target and Development Plans for HuMax-Inflam
|
|
14 Sep 2007 |
Genmab Provides Insights into IgG4 Antibodies
|
|
14 Sep 2007 |
DAHANCA Initiates Head and Neck Cancer Study with Genmab's HuMax-EGFr
|
|
13 Sep 2007 |
XOMA Initiates Phase 1 European Trial in Diabetes for XOMA 052, a Novel Anti-IL-1 Antibody Designed to Target Diabetes, Rheumatoid Arthritis and Other Inflammatory Diseases
|
|
12 Sep 2007 |
Astellas Initiates Phase II Clinical Trials for Immunosuppressant, ASP0485
|
|
11 Sep 2007 |
Merck: Erbitux Phase III Study - FLEX Increases Overall Survival in First-line Treatment of Non-Small Cell Lung Cancer
|
|
11 Sep 2007 |
Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
|
|
08 Sep 2007 |
Ablynx and Boehringer Ingelheim announce major global strategic alliance to discover, develop and commercialise novel nanobody(R) therapeutics
|
|
08 Sep 2007 |
ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
|
|
08 Sep 2007 |
Genmab announces encouraging preclinical data for Ofatumumab
|
|
06 Sep 2007 |
Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
|
